COGNITION THERAPEUTICS INC (CGTX) Stock Overview
NASDAQ:CGTX - US19243B1026 - Common Stock
CGTX Key Statistics, Chart & Performance
The current stock price of CGTX is 3.4785 USD. In the past month the price increased by 234.52%. In the past year, price increased by 280.76%.
CGTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.09 | 673.93B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 431.38B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.91 | 257.01B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.24 | 251.05B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.33 | 245.58B | ||
| MRK | MERCK & CO. INC. | 11.18 | 214.98B | ||
| PFE | PFIZER INC | 7.54 | 145.29B | ||
| SNY | SANOFI-ADR | 11.58 | 124.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.1 | 97.27B | ||
| GSK | GSK PLC-SPON ADR | 8.93 | 80.81B | ||
| ZTS | ZOETIS INC | 25.08 | 69.14B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 52.76 | 48.32B |
Related stock screener links
About CGTX
Company Profile
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 25 full-time employees. The company went IPO on 2021-10-08. The firm is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. The company is developing other product candidates in the area of synucleinopathies.
Company Info
COGNITION THERAPEUTICS INC
Suite 261, 2403 Sidney Street
Pittsburgh PENNSYLVANIA US
Employees: 27
Phone: 14127701621
COGNITION THERAPEUTICS INC / CGTX FAQ
What is the stock price of COGNITION THERAPEUTICS INC today?
The current stock price of CGTX is 3.4785 USD. The price increased by 23.79% in the last trading session.
What is the ticker symbol for COGNITION THERAPEUTICS INC stock?
The exchange symbol of COGNITION THERAPEUTICS INC is CGTX and it is listed on the Nasdaq exchange.
On which exchange is CGTX stock listed?
CGTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for COGNITION THERAPEUTICS INC stock?
10 analysts have analysed CGTX and the average price target is 3.32 USD. This implies a price decrease of -4.7% is expected in the next year compared to the current price of 3.4785. Check the COGNITION THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is COGNITION THERAPEUTICS INC worth?
COGNITION THERAPEUTICS INC (CGTX) has a market capitalization of 255.57M USD. This makes CGTX a Micro Cap stock.
How many employees does COGNITION THERAPEUTICS INC have?
COGNITION THERAPEUTICS INC (CGTX) currently has 27 employees.
Should I buy COGNITION THERAPEUTICS INC (CGTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CGTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CGTX, evaluating the profitability, health, valuation and growth aspects
- COGNITION THERAPEUTICS INC (CGTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- COGNITION THERAPEUTICS INC (CGTX) Sales and EPS estimates to see what analysts future expectations are.
- COGNITION THERAPEUTICS INC (CGTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- COGNITION THERAPEUTICS INC (CGTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- COGNITION THERAPEUTICS INC (CGTX) Stock Chart to make your own analysis
- COGNITION THERAPEUTICS INC (CGTX) Latest news and press-releases to stay up to date.
Does COGNITION THERAPEUTICS INC (CGTX) stock pay dividends?
CGTX does not pay a dividend.
When does COGNITION THERAPEUTICS INC (CGTX) report earnings?
COGNITION THERAPEUTICS INC (CGTX) will report earnings on 2025-11-11.
What is the Price/Earnings (PE) ratio of COGNITION THERAPEUTICS INC (CGTX)?
COGNITION THERAPEUTICS INC (CGTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
What is the Short Interest ratio of COGNITION THERAPEUTICS INC (CGTX) stock?
The outstanding short interest for COGNITION THERAPEUTICS INC (CGTX) is 7.3% of its float. Check the ownership tab for more information on the CGTX short interest.
CGTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CGTX. When comparing the yearly performance of all stocks, CGTX is one of the better performing stocks in the market, outperforming 99.73% of all stocks.
CGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CGTX. The financial health of CGTX is average, but there are quite some concerns on its profitability.
CGTX Financial Highlights
Over the last trailing twelve months CGTX reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS increased by 28.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -168.14% | ||
| ROE | -469.38% | ||
| Debt/Equity | 0 |
CGTX Forecast & Estimates
10 analysts have analysed CGTX and the average price target is 3.32 USD. This implies a price decrease of -4.7% is expected in the next year compared to the current price of 3.4785.